Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis

Arthritis and Rheumatism

Volumn 58, Issue 6, 2008, Pages 1796-1802

  Viguier, Manuelle ^a   Richette, Pascal ^b   Aubin, François ^c   Beylot Barry, Marie ^d,e   Lahfa, Morad ^a   Bedane, Christophe ^f   Delesalle, Franck ^g   Richard Lallemand, Marie Aleth ^h   Delaporte, Emmanuel ^g   Dubertret, Louis ^a   Bardin, Thomas ^b   Bachelez, Hervé ^a,i  

^a INSERM   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f DUPUYTREN UNIVERSITY HOSPITAL   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h HÔPITAL SAINTE MARGUERITE   (France)

ⁱ SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PSORALEN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; DACTYLITIS; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTHESITIS; FEMALE; FOLLOW UP; HUMAN; INFLAMMATORY DISEASE; MALE; MONARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; RECOMMENDED DRUG DOSE; RELAPSE; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SCORING SYSTEM; SPINE DISEASE; SYNOVITIS; TREATMENT RESPONSE;

EID: 45349107473     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23507     Document Type: Article

References (31)

1. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis [review]. Ann Rheum Dis 2005;64 Suppl 2:ii26-9.
2. Mease P. Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology [review]. Curr Rheumatol Rep 2006;8:348-54.
3. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600.
4. Lebwohl M, Tyring SK, Hamilton TK, Toth D, Glazer S, Tawfik NH, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
5. Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial [published erratum appears in JAMA 2004;291:1070]. JAMA 2003;290:3073-80.
6. Menter A, Kosinski M, Bresnahan BW, Papp KA, Ware JE Jr. Impact of efalizumab on psoriasis-specific patient-reported outcomes: results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis. J Drugs Dermatol 2004;3:27-38.
7. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, et al. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006;155:170-81.
8. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005;52:425-33.
9. Papp KA, Caro I, Leung HM, Garovoy M, Mease PJ. Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 2007;11:57-66.
10. Bang B, Gniadecki R. Severe exacerbation of psoriatic arthritis during treatment with efalizumab: a case report [letter]. Acta Derm Venereol 2006;86:456-7.
11. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005;141:31-8.
12. Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
13. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991;34:1218-27.
14. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis [review]. Ann Rheum Dis 2005;64 Suppl 2:ii3-8.
15. Vasey FB, Espinoza LR. Psoriatic arthritis. In: Calin A, editor. Spondylarthropathies. Orlando (FL): Grune & Stratton; 1984. p. 151-85.
16. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on [review] [published erratum appears in Arthritis Rheum 1999;42:1997]. Arthritis Rheum 1999;42:1080-6.
17. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
18. Fournie B, Crognier L, Arnaud C, Zabraniecki L, Lascaux-Lefebvre V, Marc V, et al. Proposed classification criteria of psoriatic arthritis: a preliminary study in 260 patients. Rev Rheum Engl Ed 1999;66:446-56.
19. Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P, et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis [review]. J Clin Pharmacol 2006;46:10-20.
20. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
21. Gottlieb AB, Hamilton T, Caro I, Kwon P, Compton PG, Leonardi CL, for the Efalizumab Study Group. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006;54(4 Suppl 1):S154-63.
22. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects [review]. Expert Opin Drug Saf 2006;5:197-209.
23. Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006;213:204-14.
24. Tom WL, Miller MD, Hurley MY, Suneja T, Kudva G, Leonardi CL, et al. Efalizumab-induced autoimmune pancytopenia. Br J Dermatol 2006;155:1045-7.
25. Kluger N, Girard C, Gonzalez V, Guillot B, Bessis D. Efalizumab-induced aseptic meningitis. Br J Dermatol 2006;155:1045-7.
26. Pincelli C, Henninger E, Casset-Semanaz F. The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from phase III clinical trials of efalizumab. Arch Dermatol Res 2006;298:329-38.
27. Shear NH, Langley RG, Ho V. Efalizumab, a reversible T-cell modulator for psoriasis [review]. J Cutan Med Surg 2006;9 Suppl 1:4-9.
28. Papp KA. Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator [review]. Drugs Today (Barc) 2004;40:889-99.
29. Lowes MA, Chamian F, Abello MV, Fuentes-Duculan J, Lin SL, Nussbaum R, et al. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005;102:19057-62.
30. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005;52:2513-8.
31. Richette P, Viguier M, Bachelez H, Bardin T. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect? J Rheumatol 2007;34:438-9.